Dr. Shang-Chiung (Charles) Chen joined Zymeworks in July 2022, bringing extensive experience in translational sciences and clinical pharmacology, with a strong focus on oncology and rare diseases. He currently serves as Vice President of Translational Sciences at Zymeworks, where he leads the Clinical Pharmacology, Pharmacometrics, Biomarker & Bioinformatics, Bioanalysis, and Toxicology functions.

Prior to joining Zymeworks, Dr. Chen built a distinguished track record of leading cross-functional teams and advancing new molecular entities from preclinical development through regulatory submission at leading pharmaceutical companies, including Genentech, Pfizer, and Travere Therapeutics. His clinical development expertise is underscored by key leadership roles in successful regulatory submissions such as KADCYLA and FILSPARI, as well as extensive interactions with global health authorities, including the FDA and EMA. He has broad experience across multiple therapeutic modalities, including antibody–drug conjugates (ADCs), T cell engagers (TCEs), immuno-oncology agents, and small molecules.

Dr. Chen received his Ph.D. in Molecular Pharmacology and Cancer Therapeutics from the State University of New York (SUNY) at Buffalo.